Alkermes (ALKS) Financial Analysis & Valuation | Quarter Chart
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable ... more
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical p... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $7.32B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IE | CEO | Blair Jackson |
| IPO Date | 1991-07-16 | CAGR | 16.52% |
| Employees | 2,050 | Website | www.alkermes.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 82.29% | Total Yield | 82.29% |
ALKS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.79B | P/E | 45.93 | Forward P/E | 24.13 | PEG | -1.16 |
| P/S | 0.04 | P/B | 0.04 | P/CF | 0.29 | P/FCF | 0.33 |
| Sales | $1.67B | Sales 1Y | 10.79% | Sales 3Y | 14.06% | Sales 5Y | 51.58% |
| EPS | $0.95 | EPS 1Y | -81.59% | EPS 3Y | -32.81% | EPS 5Y | -196.62% |
| Sales QoQ | 26.24% | EPS QoQ | -100.75% | Sales QoQ Avg | 6.72% | EPS QoQ Avg | -96.32% |
| Gross Margin | 60.7% | Operating Margin | 7.03% | Profit Margin | 3.97% | ROCE | 3.14% |
| ROA | 2% | ROE | 4% | Altman Z Score | 2.18 | Piotroski Score | 4 |
| Current Ratio | 2.19 | Quick Ratio | 1.73 | Cash Ratio | 1.04 | Op. CF Ratio | 0.22 |
| Debt/Equity | 0.87 | Debt/Assets | 0.36 | Lt Debt/Equity | 0.88 | Lt Debt/Cap. | 0.46 |
| Intrst Cov. | 16.19 | Inventory Turnover | 0.53 | Asset Turnover | 0.38 | Receivables Turnover | 3.65 |
| Enterprise Value | $8.79B | P/E Ratio | 45.93 |
| Forward P/E | 24.13 | PEG Ratio | -1.16 |
| P/S Ratio | 0.04 | P/B Ratio | 0.04 |
| P/CF Ratio | 0.29 | P/FCF Ratio | 0.33 |
| EPS | $0.95 | EPS Growth 1Y | -81.59% |
| EPS Growth 3Y | -32.81% | EPS Growth 5Y | -196.62% |
| Revenue Growth 1Y | 10.79% | Gross Margin | 60.7% |
| Operating Margin | 7.03% | Profit Margin | 3.97% |
| ROE | 4% | ROA | 2% |
| ROCE | 3.14% | Current Ratio | 2.19 |
| Quick Ratio | 1.73 | Cash Ratio | 1.04 |
| Debt/Equity | 0.87 | Interest Coverage | 16.19 |
| Altman Z Score | 2.18 | Piotroski Score | 4 |
Alkermes (ALKS) valuation & financials
Alkermes (ALKS) has a market capitalization of $7.32B and trades at a price-to-earnings ratio of 45.9. It operates in the Healthcare sector (Biotechnology).
Alkermes's revenue grew +10.8% over the last year.
Alkermes's next earnings report is scheduled for November 3, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.08. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)